Patent US3442883A successfully refreshed from Google Patents.
Patent US5145845A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5145845A Expired / Lapsed US ⏱️ 0.0 years remaining

Substituted 2-carboxylindoles having pharmaceutical activity

Assignee: Warner Lambert Co LLC
•
Filing: 1991-05-14
•
Granted: 1992-09-08
•
Expires: 2011-05-14
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention relates to novel compounds, which are derivatives of ureas, thioureas, carbamates, sulfonylureas, sulfonamides, amides, and thioamides of 2-carboxyindoles as illustrated by the formula ##STR1## The invention also relates to methods for the preparation of the novel compounds, as well as to pharmaceutical compositions or methods of use for the novel compounds. More specifically, the compounds of the present invention are useful in the treatment of neurodegenerative disorders including cerebrovascular disorders as well as in the treatment of schizophrenia or epilepsy; and as analgesics and anxiolytics.

Inventors

  • 👤 Graham Johnson
  • 👤 Thomas C. Malone
  • 👤 Po-Wai Yuen

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-08 13:30
CPC Classifications
C; C07; C07D; C07D403/00; C07D403/02; C07D403/04; C07D209/00; C07D209/02; C07D209/04; C07D209/30; C07D209/42; C07D403/06

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 551 words
A compound of the formula ##STR16## or a pharmaceutically acceptable base or acid addition salt thereof; wherein (1) Y is (a) OH; (b) OR 30 wherein R 30 is lower alkyl, phenyl, phenylalkyl wherein the alkyl is an alkylene of from one to four carbons and the phenyl is unsubstituted or substituted by from one to three substituents selected from lower alkyl, halogen, trifluoromethyl, nitro, amino, mono- or di-lower alkylamino, hydroxy, lower alkoxy, C(O)OH, and NHCOR 5 wherein R 5 is lower alkyl, lower alkenyl, phenyl, phenylloweralkyl, phenylloweralkenyl or where the phenyl is substituted as defined above; (c) NR 40 R 50 wherein R 40 and R 50 are independently hydrogen or lower alkyl; or (d) OCH 2 OR 30 wherein R 30 is as defined above; (2) R 1 , R 2 , R 3 , and R 4 are independently hydrogen, lower alkyl, halogen, trifluoromethyl, cyano, nitro, methylthio, lower alkenyl, lower alkynyl, SO 2 NH 2 , S(O) 1-2 R wherein R is hydrogen or lower alkyl, OCF 3 ; (3) A is --(CH 2 ) n --, --(CH 2 ) q CH═CH(CH 2 ) p --, ##STR17## wherein R 11 and R 13 are independently as defined below and n is an integer of 0 through 4, q is an integer of 0 or 1, p is an integer of 1 or 2; (4) R 5 is hydrogen, alkyl of from one to twenty carbons, phenyl or phenyl substituted as defined above; (5) R 6 is (a) CONR 8 R 9 , (b) COOR 8 , (c) CSR 8 , (d) S(O) 1-2 R 8 , (e) S(O) 1-2 NR 8 R 9 , or (f) CONR 8 S(O) 1-2 R 9 , wherein R 8 and R 9 are independently (i) hydrogen; (ii) alkyl of from one to twenty carbons, or alkenyl of from one to twenty carbons; (iii) (C 3 -C 6 ) cycloalkyl or (C 3 -C 6 ) cycloalkylloweralkyl; (iv) phenyl or phenyl substituted by one to three of lower alkyl, halogen, trifluoromethyl, nitro, amino, mono- or di-lower alkylamino, hydroxy, lower alkoxy, C(O)OH, NHCOR 10 wherein R 10 is lower alkyl, lower alkenyl, phenyl, phenylloweralkyl, phenylloweralkenyl, or where the phenyl is substituted as defined above, NHSO 2 R 10 wherein R 10 is as defined above, CN, CONR 10 R 11 wherein R 10 is as defined above and R 11 is hydrogen or lower alkyl, or S(O) 0-2 R 10 wherein R 10 is as defined herein; (v) phenylloweralkyl or where the phenyl is substituted as defined above; (vi) phenylloweralkenyl or where the phenyl is substituted as defined above; (vii) (CH 2 ) q R 12 wherein q is an integer of one to four and R 12 is (A) SO 3 R 13 wherein R 13 is hydrogen or lower alkyl, (B) PO 3 R 13 wherein R 13 is as defined above, (C) CO 2 R 13 wherein R 13 is as defined above, or (D) NR 14 R 15 wherein R 14 and R 15 are independently hydrogen or alkyl; or (6) R 5 and R 6 are taken together with N which form ##STR18## wherein m is an integer one or two and R 16 is lower alkyl, phenyl, phenylloweralkyl or where the phenyl is substituted as defined above.
Claim 2
Dependent Claim 551 words
A compound of the formula ##STR16## or a pharmaceutically acceptable base or acid addition salt thereof; wherein (1) Y is (a) OH; (b) OR 30 wherein R 30 is lower alkyl, phenyl, phenylalkyl wherein the alkyl is an alkylene of from one to four carbons and the phenyl is unsubstituted or substituted by from one to three substituents selected from lower alkyl, halogen, trifluoromethyl, nitro, amino, mono- or di-lower alkylamino, hydroxy, lower alkoxy, C(O)OH, and NHCOR 5 wherein R 5 is lower alkyl, lower alkenyl, phenyl, phenylloweralkyl, phenylloweralkenyl or where the phenyl is substituted as defined above; (c) NR 40 R 50 wherein R 40 and R 50 are independently hydrogen or lower alkyl; or (d) OCH 2 OR 30 wherein R 30 is as defined above; (2) R 1 , R 2 , R 3 , and R 4 are independently hydrogen, lower alkyl, halogen, trifluoromethyl, cyano, nitro, methylthio, lower alkenyl, lower alkynyl, SO 2 NH 2 , S(O) 1-2 R wherein R is hydrogen or lower alkyl, OCF 3 ; (3) A is --(CH 2 ) n --, --(CH 2 ) q CH═CH(CH 2 ) p --, ##STR17## wherein R 11 and R 13 are independently as defined below and n is an integer of 0 through 4, q is an integer of 0 or 1, p is an integer of 1 or 2; (4) R 5 is hydrogen, alkyl of from one to twenty carbons, phenyl or phenyl substituted as defined above; (5) R 6 is (a) CONR 8 R 9 , (b) COOR 8 , (c) CSR 8 , (d) S(O) 1-2 R 8 , (e) S(O) 1-2 NR 8 R 9 , or (f) CONR 8 S(O) 1-2 R 9 , wherein R 8 and R 9 are independently (i) hydrogen; (ii) alkyl of from one to twenty carbons, or alkenyl of from one to twenty carbons; (iii) (C 3 -C 6 ) cycloalkyl or (C 3 -C 6 ) cycloalkylloweralkyl; (iv) phenyl or phenyl substituted by one to three of lower alkyl, halogen, trifluoromethyl, nitro, amino, mono- or di-lower alkylamino, hydroxy, lower alkoxy, C(O)OH, NHCOR 10 wherein R 10 is lower alkyl, lower alkenyl, phenyl, phenylloweralkyl, phenylloweralkenyl, or where the phenyl is substituted as defined above, NHSO 2 R 10 wherein R 10 is as defined above, CN, CONR 10 R 11 wherein R 10 is as defined above and R 11 is hydrogen or lower alkyl, or S(O) 0-2 R 10 wherein R 10 is as defined herein; (v) phenylloweralkyl or where the phenyl is substituted as defined above; (vi) phenylloweralkenyl or where the phenyl is substituted as defined above; (vii) (CH 2 ) q R 12 wherein q is an integer of one to four and R 12 is (A) SO 3 R 13 wherein R 13 is hydrogen or lower alkyl, (B) PO 3 R 13 wherein R 13 is as defined above, (C) CO 2 R 13 wherein R 13 is as defined above, or (D) NR 14 R 15 wherein R 14 and R 15 are independently hydrogen or alkyl; or (6) R 5 and R 6 are taken together with N which form ##STR18## wherein m is an integer one or two and R 16 is lower alkyl, phenyl, phenylloweralkyl or where the phenyl is substituted as defined above.
Claim 3
Dependent Claim 9 words
A compound of claim 1 wherein Y is OH.
Claim 4
Dependent Claim 13 words
A compound of claim 1 wherein A is --(CH 2 ) n --.
Claim 5
Dependent Claim 13 words
A compound of claim 1 wherein A is --CH═CH(CH 2 ) 1-2 .
Claim 6
Dependent Claim 13 words
A compound of claim 1 wherein A is --CH 2 CH═CHCH 2 --.
Claim 7
Dependent Claim 9 words
A compound of claim 1 wherein A is ##STR19##
Claim 8
Dependent Claim 14 words
A compound of claim 1 wherein R 6 is CONR 8 R 9 .
Claim 9
Dependent Claim 12 words
A compound of claim 1 wherein R 6 is COOR 8 .
Claim 10
Dependent Claim 12 words
A compound of claim 1 wherein R 6 is CSR 8 .
Claim 11
Dependent Claim 14 words
A compound of claim 1 wherein R 6 is S(O) 1-2 R 8 .
Claim 12
Dependent Claim 16 words
A compound of claim 1 wherein R 6 is S(O) 1-2 NR 8 R 9 .
Claim 13
Dependent Claim 16 words
A compound of claim 1 wherein R 6 is CONR 8 S(O) 1-2 R 9 .
Claim 14
Dependent Claim 17 words
A compound of claim 1 wherein R 5 and R 6 together with the N are ##STR20##
Claim 15
Dependent Claim 88 words
A compound of claim 1 which is (1) Methyl 4,6-dichloro-3-[2-[[(phenylamino)carbonyl]amino]ethyl]-1H-indole-2-carboxylate; (2) Methyl 4,6 dichloro 3-[2 [[[(phenylmethyl)amino]carbonyl]amino]ethyl]-1H-indole-2-carboxylate; (3) Methyl 4,6-dichloro-3-[2-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]ethyl]-1H -indole-2-carboxylate; (4) Methyl 4,6-dichloro 3-[2 [[[(2-methylphenylamino]carbonyl]amino]ethyl]-1H -indole-2 carboxylate; (5) Methyl 4,6-dichloro-3-[2-(2-oxo-3-phenyl 1-imidazolidinyl)ethyl]-1H-indole-2carboxylate; (6) 4,6-Dichloro-3 [2-[[(phenylamino)carbonyl]amino]ethyl]-1H-indole-2-carboxylic acid; (7) 4,6-Dichloro-3-[2-[[[(phenylmethyl)amino]carbonyl]amino]ethyl]-1H-indole-2-carboxylic acid; (8) 4,6-Dichloro-3-[2 [[[(3,5-dichlorophenyl)amino]carbonyl]amino]ethyl]-1H -indole-2-carboxylic acid; (9) 4,6-Dichloro-3-[2 [[[(2-methylphenyl)amino]carbonyl]amino]ethyl]-1H-indole-2-carboxylic acid; (10) 4,6-Dichloro-3 [2 (2 oxo-3 phenyl 1-imidazolidinyl)ethyl]-1H indole-2-carboxylic acid; (11) 4,6-Dichloro-3-[[(phenylamino)carbonyl]amino]-1H indole 2 carboxylic acid; (12) 4,6-Dichloro-3 [[[(phenylamino)carbonyl]amino]methyl]-1H-indole-2-carboxylic acid; (13) 4,6-Dichloro-3-[3-[[(phenylamino)carbonyl]amino]propyl]-1H-indole 2 carboxylic acid; (14) 4,6-Dichloro-3-[3-(2-oxo-3-phenyl-1-imidazolidinyl)propyl]-1H-indole-2-carboxylic acid; (15) 4,6-Dichloro 3-[(2-oxo-3-phenyl-1-imidazolidinyl)methyl]-1H-indole-2-carboxylic acid; (16) 4,6-Dichloro-3-(2-oxo-3-phenyl-1-imidazolidinyl)-1H-indole-2-carboxylic acid; (17) 4,6-Dichloro-3-[[[(phenylsulfonyl)amino]carbonyl]amino]-1H-indole-2-carboxylic acid; and (18) 4,6-Dichloro-3-[2-[[[(phenylsulfonyl)amino]carbonyl]amino]ethyl]-1H-indole-2-carboxylic acid.
Claim 16
Dependent Claim 24 words
A pharmaceutical composition comprising a therapeutically effective amount of a compound of the Formula I of claim 1 together with a pharmaceutically acceptable carrier.
Claim 17
Dependent Claim 39 words
A method for treating disorders responsive to the blockade of glutamic and aspartic acid receptors comprising administration to a patient in need thereof an effective amount of a compound of Formula I of claim 1 in unit dosage form.

References Cited (Backward Citations)

US3182071A Cited
US3364224A Cited
US3574737A Cited
US3472870A Cited
US4980368A Cited
US4960786A Cited
EP0394905A2 Cited
EP0396124A2 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-09-08 1996-03-09 1996-09-08 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-09-08 2000-03-09 2000-09-08 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-09-08 2004-03-09 2004-09-08 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag